It’s been a lovely bluebell season, but I’m hearing some of the blossoms might be unwanted intruders. How can that be true? There is more than one kind of bluebell and concerns are growing that the ...

Integration strengthens Quantum Health's ability to help employers and members manage everyday prescription drug costs within its existing navigation experience The partnership improves Quantum Health ...

Bluebell season has arrived, and while this wild flower may be beautiful to look at, it's crucial to understand the risks it poses to dogs. Also referred to as Hyacinthoides non-scripta and classified ...

Bluebell season has arrived and while the wildflower might be attractive to look at, it's crucial to understand its toxicity to dogs. Also known as Hyacinthoides non-scripta and classed as both a ...

Type to search articles, cases, and authors. Press ↵ to view all results. (Jonathan Newton/The Washington Post via Getty Images) Courtly Observations is a recurring series by Erwin Chemerinsky that ...

Scripta allows consumers to compare prescription prices, coupons, and insurance options in one place, helping patients and employers find affordable meds and smarter choices. As prescription drug ...

Scripta’s unique approach is based on the concept that transcription factors, the master controllers of gene expression, are core drivers of disease and act as detailed and dynamic maps of the ...

$12 million seed funding round led by Oxford Science Enterprises and Apollo Health Ventures, with AlbionVC, YZR Capital, and Parkwalk Advisors, and support from Oxford University Innovation Scripta ...

Scripta Insights is partnering with RxSaveCard to help self-insured employers meet their fiduciary obligations and cut prescription drug costs by giving members access to affordable medication options ...

Scripta Insights, a company that develops pharmacy navigation solutions for self-insured employers, health plans and members, is entering into a strategic partnership with RxSaveCard, which offers ...

Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study. This is an ASCO Meeting Abstract from the ...